Author

Jin Hu

Institutions: University of Shanghai for Science and Technology, Changhai Hospital

Observed institutions: University of Shanghai for Science and Technology, Changhai Hospital, CStone Pharmaceuticals (China)

ORCID: 0009-0000-9134-763X

Observed ORCID: 0009-0000-9134-763X

OpenAlex ID: A5076949720

Middle Meningeal Artery Embolization for Nonacute Subdural Hematoma

2024 · Jianmin Liu, Wei Ni, et al. · New England Journal of Medicine · 243

Clinical Benefit of Avapritinib in KIT- Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

2023 · Michael C. Heinrich, Xinhua Zhang, et al. · Clinical Cancer Research · 9

Data from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

2024 · Michael C. Heinrich, Xinhua Zhang, et al.

Supplementary Table S1 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

2024 · Michael C. Heinrich, Xinhua Zhang, et al.

Supplementary Table S2 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

2024 · Michael C. Heinrich, Xinhua Zhang, et al.

Data from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

2024 · Michael C. Heinrich, Xinhua Zhang, et al.

Supplementary Figure S1 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

2024 · Michael C. Heinrich, Xinhua Zhang, et al.

Supplementary Table S1 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

2024 · Michael C. Heinrich, Xinhua Zhang, et al.

Supplementary Figure S1 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

2024 · Michael C. Heinrich, Xinhua Zhang, et al.

Supplementary Table S2 from Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies

2024 · Michael C. Heinrich, Xinhua Zhang, et al.

Works count: 10

Citation count: 252

H-index: 2

I10-index: 1